{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:23:13Z","timestamp":1770747793355,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009399","name":"Macular Disease Foundation Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ajo.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T10:17:07Z","timestamp":1552126627000},"page":"105-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Five-Year Real-World Outcomes of Occult and Classic Choroidal Neovascularization: Data From the Fight Retinal Blindness! Project"],"prefix":"10.1016","volume":"204","author":[{"given":"Alessandro","family":"Invernizzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vuong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin","family":"Teo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Barthelmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Fung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Gillies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ajo.2019.03.001_bib1","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/archopht.1991.01080090066027","article-title":"Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2019.03.001_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0002-9394(98)00145-7","article-title":"Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes","volume":"126","author":"Grossniklaus","year":"1998","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2019.03.001_bib3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0039-6257(88)90052-5","article-title":"Age-related macular degeneration","volume":"32","author":"Bressler","year":"1988","journal-title":"Surv Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2019.03.001_bib4","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/IAE.0b013e3181e7976b","article-title":"Do we need a new classification for choroidal neovascularization in age-related macular degeneration?","volume":"30","author":"Freund","year":"2010","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.ajo.2019.03.001_bib5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ajo.2014.07.006","article-title":"The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration","volume":"158","author":"Jung","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.001_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/archopht.1997.01100150347006","article-title":"Occult choroidal neovascularization in age-related macular degeneration. A natural history study","volume":"115","author":"Stevens","year":"1997","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2019.03.001_bib7","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/archopht.1996.01100130396006","article-title":"Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration. Macular Photocoagulation Study Group","volume":"114","year":"1996","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2019.03.001_bib8","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/archopht.1991.01080090056026","article-title":"Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2019.03.001_bib9","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1001\/archopht.1991.01080090044025","article-title":"Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2019.03.001_bib10","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","volume":"117","year":"1999","journal-title":"Arch Ophthalmol"},{"issue":"14","key":"10.1016\/j.ajo.2019.03.001_bib11","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ajo.2019.03.001_bib12","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/archopht.125.11.1460","article-title":"Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial","volume":"125","author":"Chang","year":"2007","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2019.03.001_bib13","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2019.03.001_bib14","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ophtha.2018.01.004","article-title":"Development and course of scars in the Comparison of Age-related Macular Degeneration Treatments Trials","volume":"125","author":"Daniel","year":"2018","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2019.03.001_bib15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/bjophthalmol-2013-303117","article-title":"Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration","volume":"98","author":"Danis","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2019.03.001_bib16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ophtha.2016.10.010","article-title":"Dual antagonism of PDGF and VEGF in neovascular age-related macular degeneration: a phase IIb, multicenter, randomized controlled trial","volume":"124","author":"Jaffe","year":"2017","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2019.03.001_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ypmed.2007.08.012","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"45","author":"von Elm","year":"2007","journal-title":"Prev Med"},{"issue":"1","key":"10.1016\/j.ajo.2019.03.001_bib18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/IAE.0b013e318296b271","article-title":"Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project","volume":"34","author":"Gillies","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2019.03.001_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2016.04.012","article-title":"Defining a minimum set of standardized patient-centered outcome measures for macular degeneration","volume":"168","author":"Rodrigues","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2019.03.001_bib20","first-page":"198","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2","volume":"119","author":"Bressler","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2019.03.001_bib21","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.ophtha.2015.02.009","article-title":"Two-year outcomes of \u201ctreat and extend\u201d intravitreal therapy for neovascular age-related macular degeneration","volume":"122","author":"Arnold","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2019.03.001_bib22","author":"Therneau"},{"key":"10.1016\/j.ajo.2019.03.001_bib23","series-title":"R: A Language and Environment for Statistical Computing","year":"2016"},{"issue":"1","key":"10.1016\/j.ajo.2019.03.001_bib24","first-page":"20","article-title":"Segmented: an R package to fit regression models with broken-line relationships","volume":"8","author":"Muggeo","year":"2008","journal-title":"R News"},{"issue":"1","key":"10.1016\/j.ajo.2019.03.001_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.001_bib26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0002-9394(03)00223-X","article-title":"Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1","volume":"136","author":"Blinder","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.001_bib27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ajo.2003.09.042","article-title":"Choroidal neovascularization","volume":"137","author":"Grossniklaus","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2019.03.001_bib28","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/IAE.0000000000000827","article-title":"Intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: 5-year results of the Pan-American Collaborative Retina Study Group","volume":"36","author":"Arevalo","year":"2016","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.ajo.2019.03.001_bib29","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2019.03.001_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ophtha.2012.07.042","article-title":"Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration","volume":"120","author":"Ying","year":"2013","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2019.03.001_bib31","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.1167\/iovs.15-16494","article-title":"Baseline predictors for good versus poor visual outcomes in the treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF therapy","volume":"56","author":"Chae","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.ajo.2019.03.001_bib32","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.ophtha.2015.08.015","article-title":"Association of baseline characteristics and early vision response with 2-year vision outcomes in the Comparison of AMD Treatments Trials (CATT)","volume":"122","author":"Ying","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2019.03.001_bib33","doi-asserted-by":"crossref","first-page":"4367631","DOI":"10.1155\/2016\/4367631","article-title":"Epidemiological and clinical baseline characteristics as predictive biomarkers of response to anti-VEGF treatment in patients with neovascular AMD","volume":"2016","author":"Tsilimbaris","year":"2016","journal-title":"J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.001_bib34","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ophtha.2014.10.001","article-title":"Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.001_bib35","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ophtha.2015.10.034","article-title":"Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)","volume":"123","author":"Daniel","year":"2016","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2019.03.001_bib36","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939419300972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939419300972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:39:43Z","timestamp":1757597983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939419300972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":36,"alternative-id":["S0002939419300972"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2019.03.001","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five-Year Real-World Outcomes of Occult and Classic Choroidal Neovascularization: Data From the Fight Retinal Blindness! Project","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}